AI-driven Precision and Efficiency
Oncosoft
In every step from planning to chart close-out, Oncosoft is always there. You focus on patients, we focus on you.
OncoStudio provides drawings of all organs within an average of 3 minutes on a local workstation.
The AI automatically detects the treatment site and prepares organ contour samples without any additional user intervention.
It operates vendor-neutrally, interfacing with all commercially available hardware and software according to the DICOM standard.
It generates consistent contours resembling peer-reviewed quality with expert-level accuracy.
It provides over 100 structures of organs at risk (OAR) and clinical target volumes (CTV) for CT, MR, and cone-beam CT.
It optimizes and provides organ templates and contour styles tailored to the characteristics of each institution.
Our solution offers a data-centric workflow and provides efficient data processing capabilities adhering to international standards.
Data Workflow
Our solution provides an intuitive workflow aligned with data-centric processes in radiation oncology.
Global Standards
We offer software compliant with global standards for medical imaging and broader healthcare information, supporting DICOM and HL7 FHIR.
Feedback System
We prioritize customer satisfaction, promptly responding to on-site requests and suggestions, with a customer-first approach. We adapt quickly to meet their needs.
Expert teams
We partner with clinical experts for rapid on-site analysis, enhancing our products based on insights. Our development team promptly responds to analysis-driven requirements
We actively pursue partnerships for product R&D.
Hospitals using
Oncosoft are increasing annually.
We have successfully progressed with our solution until 2022.
It reduces time to just
5 minutes and boosts productivity.
We aim to enhance our product based on diverse customer feedback.
Internally, we continuously retrain the model with additional data, provide updates to the architecture, and validate the model. Once the model has been validated internally, we periodically deploy it.
Absolutely. If the requested organ is deemed critical for radiation therapy in a general context, we can prioritize it in our internal labeling tasks and provide updates accordingly. However, updating the AI model requires hundreds of data samples, so the process may take several months. Collaboration in research can expedite this process, and we welcome any partnership requests!
In the past, we mainly utilized 3D models. However, 2D models offer advantages in detail resolution due to the absence of GPU memory constraints, although they may encounter connectivity issues between slices. On the other hand, 3D models often excel in connectivity but may have limitations in detail resolution. In the new development version, we aim to enhance the efficiency of AI model inference, leveraging the strengths of both 2D and 3D models while mitigating their weaknesses.
Currently, we provide over 100 normal organs and clinical target volumes (CTV) based on CT imaging. By 2025, we aim to expand our offerings to include over 200 structures. Additionally, we are developing AI models for various imaging techniques such as MRI, Cone-beam CT (CBCT), and Megavoltage CT (MVCT), which will be distributed to users through license renewals in the near future. In the long term, we are also working on providing automatic segmentation information for Gross target volume (GTV)!
Yes, we are currently developing a new version of OncoStudio, and we plan to introduce a cloud-based product in the first half of 2025.
Subscribe to learn about upgrades and services for our product.
